Research & Development

Fordras S.A. finds its origin in the R&D tradition of SOLAR CHEMICAL S.A., a group of European chemical companies, which, over the years, has led to the filing of numerous patents throughout the world.

Our competitive edge comes in great part from our ability to remain at the forefront of innovation through proprietary products, technologies and applications, having invested from the inception in important resources toward research and development. Consequently, Fordras S.A. holds several patents and patents pending on a broad range of applications for egg-derived proteins and other biological products. In fact, Fordras was the first company to recognize the value of Lysozyme in the food industry by developing its’ application in dairy products, particularly in the process of cheese making.

Later, Fordras S.A. and its world-class staff of scientists and researchers led the way in developing the use of Lysozyme in wine-making and brewing. Through these efforts, Fordras was able to obtain important use patents associated with the application of Lysozyme in fermented beverages.

Currently, Fordras continues to lead the way by financing new research programs, in- house as well as at prestigious institutions such as Oregon State University, Universit√° di Udine, ITV France, AWRI (Australian Wine Research Institute) and The University of Wisconsin. In early 2005, one of Fordras’ sponsored research program at OSU, (which focused on the use of Lysozyme in food packaging and coating materials), led to the development of a proprietary technology in that field.


Additionally, Fordras S.A. has been a forerunner in developing the use of Avidin as a marker in the treatment of tumors. This particular research program, initiated in 1994 in collaboration with the European Institute of Oncology, is entering its final phase this year. This revolutionary radioimmunology technique “which has showed virtually no toxicity, has successfully been applied to the treatment of a brain tumor called gliobastoma1

Current and future research programs are dedicated to the development of new applications for Lysozyme, Avidin and Ovalbumin for human and animal health, in consumer products and in the food markets, as well as to the production and uses of additional synergic natural products.

At Fordras we believe that in order to successfully bring one’s R&D pipeline to market, it is necessary to establish a rigorous and effective Regulatory program. In this case, once again Fordras has been the leader. Through the strength of its’ pharmaceutical background along with sensitivity to the safety needs of the consumers, Fordras often anticipated government regulations. As shown in the timetable below, Fordras was the first company to obtain important recognitions and approval from governmental agencies and organizations, including GRAS status. Today, Fordras remains the only company with a Drug Master File for the use of Lysozyme in pharmaceutical applications. Recently, thanks to Fordras’ efforts, Lysozyme was approved for use in organic products by the USDA.

Regulatory Status Chart


Currently, Fordras is interacting with both the European Commission and the TTB to address the issue of labeling in certain foods, obtained CGMP certification for the production of Avidin at its expanded laboratory facility in Switzerland.

1This is a quote from the linked website above.